Following his rehabilitation, Lubotzky pursued a medical degree at the
Hebrew University Hadassah Medical School, qualified as a doctor, and specialized in
pediatrics at the
Shaare Zedek Hospital in
Jerusalem. and continued to a Neurology Fellowship. Additionally, Lubotzky completed a fellowship in Neonatal Neurology at
The Hospital for Sick Children (SickKids) in
Toronto,
Canada. Lubotzky conducted research in the lab of professor
Haim Cedar and became a PhD student under Professor Yuval Dor and Ruth Shemer at the Hebrew University's Department of Developmental Biology and Cancer Research, who works on methylation patterns of circulating
cell-free DNA (cfDNA). Lubotzky was recognized for his studies on cfDNA as cancer diagnostic markers, and his research has earned him several honors, including the
Israel Cancer Research Fund (ICRF) cancer grant and in 2019, he was awarded The James Sivartsen Prize in Cancer Research by The Hebrew University. In 2020 his research team received a prestigious grant of $500,000 from the
Bill & Melinda Gates Foundation and
Alzheimer's Drug Discovery Foundation towards their research on early diagnosis of
Alzheimer's disease based on blood tests. In 2021 he received the Joint Award of the National Institute of Psychobiology in Israel (NIPI) and the Israeli Society of Biological Psychiatry. In 2021 he was awarded a
PhD for a thesis entitled: "Liquid Biopsies Reveal Collateral Tissue Damage in Cancer and Brain Damage in Neural Pathologies". His findings demonstrated that metastatic tumors cause collateral tissue damage, releasing cfDNA from affected organs, and that cfDNA methylation patterns can help pinpoint metastases and their tissue origins. In 2022 he received The
Rothschild Fellowship for young scholars of outstanding academic merit. In the same year, Lubotzky and his colleagues published a study showing that
brain cells die during
psychotic episodes, with higher levels of brain-derived cfDNA detected in patients experiencing psychotic symptoms, compared to healthy controls. The finding would serve as a proof of concept for brain-derived cell-free DNA as biomarkers of psychosis. In 2023, Lubotzky received the
Ben Barres Spotlight Award by
eLife for his research towards understanding brain dynamics. ==Writing==